Arkansas Children’s Little Rock will install in its hospital a Truix neo for functional brain imaging. On Friday (Aug. 24), magnetoencephalography (MEG) technology provider Megin, formerly Elekta Oy, announced the hospital had signed an agreement to purchase the Truix neo. The purchase price was not disclosed.
MEG is a non-invasive diagnostic device and measures magnetic activity generated by neurons in the brain. Truix neo is used in the diagnosis and assessment of complex neurological disruptions and can detect neural events with millimeter accuracy and millisecond resolution. The detection capability can have an impact on patient diagnoses, including epilepsy, brain tumors, traumatic brain injury, post-traumatic stress disorder and autism.
“MEG is a state-of-the-art device that can precisely localize the source of seizures within the brain to help provide a life-changing cure for select children with uncontrolled epilepsy,” said Gregory Sharp, chief of neurology and Arkansas Children’s. “This asset will lead to new understandings of neurologic disorders through research.”
The Truix neo is expected to be installed by the end of 2018.
“We are very excited to be working with Arkansas Children’s hospital and providing our latest technology in functional brain imaging for their patients,” said Janne Huhtala, CEO of Megin. “The information gained through the use of MEG can have a significant impact on patients who are otherwise left with few definitive answers when faced with surgery.”